- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.07. | Profusa, Inc.: Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs | 338 | GlobeNewswire (Europe) | BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement... ► Artikel lesen | |
| 27.07. | Profusa Announces Signing Of Non-Binding Term Sheet For Acquisition Of Commercial-Stage Diagnostics Company | 2 | pulse2.com | ||
| 27.07. | Profusa inks term sheet to merge with $111M health diagnostics firm; appoints Jack Stover as CEO | 1 | Seeking Alpha | ||
| PROFUSA Aktie jetzt für 0€ handeln | |||||
| 27.07. | Profusa unterzeichnet Absichtserklärung zur Übernahme eines Diagnostikunternehmens | 2 | Investing.com Deutsch | ||
| 27.07. | Profusa signs term sheet to acquire diagnostics company | 1 | Investing.com | ||
| 27.07. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | Profusa, Inc.: Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company | 284 | GlobeNewswire (Europe) | BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding... ► Artikel lesen | |
| 06.07. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Profusa approves 1-for-25 reverse stock split; shares tumble | 1 | Seeking Alpha | ||
| 02.07. | Profusa kündigt Aktienzusammenlegung im Verhältnis 1:25 mit Wirkung zum 7. Juli an | 1 | Investing.com Deutsch | ||
| 02.07. | Profusa announces 1-for-25 reverse stock split effective July 7 | 1 | Investing.com | ||
| 02.07. | Profusa, Inc.: Profusa Announces 1-for-25 Reverse Stock Split | 149 | GlobeNewswire (Europe) | BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology... ► Artikel lesen | |
| 24.06. | Profusa, Inc.: Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts | 216 | GlobeNewswire (Europe) | BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved... ► Artikel lesen | |
| 23.06. | Profusa Aktionäre genehmigen wichtige Vorstandsvorschläge inklusive Aktienzusammenlegung | 1 | Investing.com Deutsch | ||
| 23.06. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Profusa submits response to European regulator for device approval | 2 | Investing.com | ||
| 12.06. | Profusa, Inc.: Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee Oxygen Platform | 243 | GlobeNewswire (Europe) | BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its... ► Artikel lesen | |
| 10.06. | Profusa CEO urges shareholders to vote on Nasdaq listing proposals | 1 | Investing.com | ||
| 08.06. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,910 | +1,72 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| HIMS & HERS HEALTH | 26,220 | +1,94 % | Hims & Hers-Aktie: Folgt der nächste Wachstumsturbo? | Die Aktie von Hims & Hers Health hat sich in den vergangenen Jahren zu einem der spektakulärsten Wachstumswerte im Gesundheitssektor entwickelt. Die operativen Kennzahlen sprechen weiterhin für erhebliches... ► Artikel lesen | |
| CERENOME | 3,240 | -1,37 % | Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective... ► Artikel lesen | |
| HEALWELL AI | 0,435 | +0,93 % | HEALWELL AI kündigt Telefonkonferenz zur Erörterung der Finanzergebnisse des zweiten Quartals 2026 für den 7. August 2026 an | HEALWELL AI wird am Freitag, den 7. August 2026, um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz und einen gleichzeitigen Webcast
abhalten
TORONTO, ON, 4. August 2026... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,430 | +0,70 % | Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test | Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settings
SALT LAKE... ► Artikel lesen | |
| ORGANON | 11,630 | -1,06 % | Organon: $81 Million Jada Gain Lifts GAAP Profit 68% As Adjusted Earnings Fall 29% | ||
| VERU | 2,295 | -0,65 % | Veru Inc.: Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss | ||
| CLOVER HEALTH INVESTMENTS | 4,010 | -0,99 % | CLOVER HEALTH INVESTMENTS, CORP. /DE - 8-K, Current Report | ||
| ELEKTA | 4,606 | +2,77 % | Elekta AB: Elekta presents financial targets and detailed outlook ahead of Capital Markets Day | STOCKHOLM - Elekta (EKTA-B.ST) today presents new mid-term financial targets and a more detailed outlook for fiscal year (FY) 2026/2027 ahead of its Capital Markets Day in Stockholm.
Elekta is planning... ► Artikel lesen | |
| SENSEONICS | 4,500 | +0,90 % | Senseonics outlines $62M-$66M 2026 revenue guidance as it raises gross margin target to 58%-61% | ||
| IMUNON | 1,380 | +1,47 % | Imunon Q2 2026 Earnings Preview | ||
| PERSPECTIVE THERAPEUTICS | 2,528 | -1,02 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results | ||
| AXOGEN | 38,760 | +0,73 % | Trace Biosciences Raises Strategic Investment From Axogen | ||
| NIAGEN BIOSCIENCE | 2,580 | 0,00 % | Niagen Bioscience, Inc: Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 | Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience's lead investigational candidate for rare pediatric diseasesEvotec brings deep drug development... ► Artikel lesen | |
| AXE COMPUTE | 7,900 | +8,97 % | Axe Compute Inc: Axe Compute Secures $1.5 Billion Five-Year Dedicated AI Infrastructure Contract, Surpassing $3 Billion in 2026 Signed Contracted Value | Five-year, $1.5 billion B300 cluster contract lifts 2026 signed contracts above $3 billion and is expected to increase ARR to roughly $696 million.More than $534 million in cash prepayments power... ► Artikel lesen |
Das Unternehmen PROFUSA INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,026 (-2,72 %) liegt der Kurs bei 0,914 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFUSA INC finden Sie auf Wallstreet Online.